Biosimilars Regulation in the US: The Challenges

被引：0
|
作者：
Ridley-Smith, Philip [1 ]
机构：
[1] RecipharmCobra Biol, Keele, Staffs, England
来源：
BIOPHARM INTERNATIONAL | 2010年 / 23卷 / 11期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [1] Challenges with the Introduction of Biosimilars in the US
    Stevenson, James G.
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2016, 8 (03) : 93 - 96
  • [2] Challenges and Opportunities for Biosimilars Developers in the US
    Ritter, Amy
    Barry, Nora
    BIOPHARM INTERNATIONAL, 2012, 25 (09) : 24 - 25
  • [3] Development and Regulation of Biosimilars: Current Status and Future Challenges
    Asterios S. Tsiftsoglou
    Sol Ruiz
    Christian K. Schneider
    BioDrugs, 2013, 27 : 203 - 211
  • [4] Development and Regulation of Biosimilars: Current Status and Future Challenges
    Tsiftsoglou, Asterios S.
    Ruiz, Sol
    Schneider, Christian K.
    BIODRUGS, 2013, 27 (03) : 203 - 211
  • [5] Safety and toxicity of biosimilars-EU versus US regulation
    Blank, Tobias
    Netzer, Tilo
    Hildebrandt, Wolfram
    Vogt-Eisele, Angela
    Kaszkin-Bettag, Marietta
    GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2013, 2 (03): : 144 - 150
  • [6] US to accept biosimilars?
    Houlton, Sarah
    CHEMISTRY & INDUSTRY, 2007, (13) : 6 - 6
  • [7] US debut for biosimilars
    Houlton, Sarah
    CHEMISTRY & INDUSTRY, 2015, 79 (04) : 25 - 25
  • [8] PRICES OF BIOSIMILARS IN THE US
    Gannu, L.
    Daniels, K.
    Seoane-Vazquez, E.
    Szeinbach, S. L.
    VALUE IN HEALTH, 2017, 20 (05) : A33 - A33
  • [9] Adalimumab and the Challenges for Biosimilars
    Gellad, Walid F.
    Good, Chester B.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (22): : 2171 - 2172
  • [10] Bioanalytical challenges of biosimilars
    Islam, Rafiq
    BIOANALYSIS, 2014, 6 (03) : 349 - 356
12345